Penggunaan Montelukast dalam Terapi Asma Bronkial dan Rinitis Alergi
DOI:
https://doi.org/10.55175/cdk.v48i5.72Keywords:
Antagonis reseptor leukotrien, asma, montelukast, rinitis alergiAbstract
Montelukast merupakan antagonis reseptor leukotrien (LTRA) oral yang diindikasikan untuk terapi asma kronik, profilaksis bronkokonstriksi yang diinduksi latihan fisik, serta meredakan gejala rinitis alergi, baik musiman maupun sepanjang tahun. Montelukast direkomendasikan sebagai monoterapi untuk mengontrol asma, khususnya pada anak, dan sebagai terapi tambahan terhadap ICS (inhalation corticosteroid) atau alternatif terhadap penambahan LABA (long acting beta agonist). Selain itu, montelukast oral direkomendasikan pada dewasa dan anak dengan rinitis alergi musiman dan pada anak prasekolah dengan rinitis alergi sepanjang tahun.
Montelukast is an oral leukotriene receptor antagonist (LTRA) indicated for the treatment of chronic asthma, prophylaxis of exercise-induced bronchoconstriction, and for the relief of symptoms of both seasonal and perennial allergic rhinitis. LTRA is recommended as monotherapy to control asthma, especially in children, and as an adjunct therapy to ICS (inhalation corticosteroid) or an alternative to the addition of LABA (long acting beta agonist). Oral montelukast are also recommended for adults and children with seasonal allergic rhinitis and in preschool children with perennial allergic rhinitis.
Downloads
References
Neighboun H, Mclvor A. Montelukast in the treatment of asthma and allergic rhinitis. Clin. Pract.2013;10(3):257-63.
Badri T, Takov V. Montelukast [Internet]. 2019 [cited 2019 Sept 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459301/?report=printable
Hon KLE, Leung TF, Leung AKC. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014;8:839-50.
Capra V, Thompson MD, Sala A, Cole DE, Folco G, Rovati GE. Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends. Med. Res. Rev. 2007;27(4):469-527.
Peters-Golden M, Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann. Allergy Asthma Immunol. 2005;94(6):609-18.
Chaudhury A, Gaude GS, Hattiholi J. Effects of oral montelukast on airway function in acute asthma: A randomized trial. Lung India 2017;34(4):349-54.
Nagao M, Ikeda M, Fukuda N, Habukawa C, Kitamura T, Katsunuma T, et al. Early control treatment with montelukast in preschool children with asthma: A randomized controlled trial. Allergol Int. 2018;67(1):72-78. doi: 10.1016/j.alit.2017.04.008.
Cingi C, Gunhan K, Gage-White L, Unlu H. Efficacy of leukotriene antagonists as concomitant therapy in allergic rhinitis. Laryngoscope. 2010;120(9):1718-23.doi:10.1002/lary.20941.
Kaur G, Dhingra R, Singh M, Kaur M. Montelukast: a better alternative than antihistaminics in allergic rhinitis. Int J Otorhinolaryngol Head Neck Surg 2017;3(2):317-22.
Jindal A, Suriyan S, Sagadevan S, Narasimhan M, Shanmuganathan A, Vallabhaneni V, et al. Comparison of oral montelukast and intranasal fluticasone in patients with asthma and allergic rhinitis. J Clin Diagn Res. 2016;10(8): OC06–OC10.
Ikram A, Kumar V, Taimur M, Kham MA, Fareed S, Barry HD. Role of montelukast in improving quality of life in patients with persistent asthma. Cureus 2019;11(6):e5046. doi:10.7759/cureus.5046
2019 GINA pocket guide [Internet]. 2019 [cited 2019 Sept 27]. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guidewms.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
